Nutritional composition for reducing uric acid

Through the composition of celery seed extract, vitamin C and vitamin B, the problem of reducing uric acid in the prior art is solved, safe and effective uric acid reduction and gout prevention are achieved, and cardiovascular protection effect is achieved.

CN118985903APending Publication Date: 2024-11-22SHENZHEN AUSA PHARMA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310553131.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce uric acid levels, and common drugs have side effects, which are difficult to use for a long time, and the effectiveness of controlling diet to reduce uric acid is limited.

Method used

Using celery seed extract, vitamin C and vitamin B compositions, through the action of uric acid formation and decomposition mechanisms, a safe and effective composition is provided to reduce uric acid levels, including an effective amount of celery seed extract, vitamin C. The ratio to vitamin B is 200-1000:20-85:1-6, and different dosage forms are prepared with auxiliary materials.

Benefits of technology

It significantly reduces uric acid levels, promotes uric acid excretion, prevents gout attacks, relieves pain, is safe and has no side effects, and has the function of assisting in preventing cardiovascular diseases, and is more effective than the application of a single component.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a nutritional composition with an effect of reducing uric acid. The nutritional composition consists of a celery seed extract, vitamin C, vitamin B and a proper amount of auxiliary materials. The nutritional composition disclosed by the invention not only can reduce the uric acid level, but also can promote uric acid excretion, so that the uric acid level of a patient with hyperuricemia is continuously controlled.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a nutritional composition, more specifically, to a composition product suitable for preventing and reducing uric acid levels. The present invention belongs to the field of health. Background Art

[0002] The "White Paper on Hyperuricemia and Gout Trends in 2021" shows that hyperuricemia in my country is showing a clear upward and younger trend. Hyperuricemia refers to the fasting blood uric acid level of two different days in a normal purine diet state, which is higher than 420μmol / L for men and higher than 360μmol / L for women. Uric acid is the final product of purine metabolism in the human body. Excessive production or insufficient excretion will lead to increased uric acid in the blood. When the concentration of uric acid in the blood exceeds the ability of the blood to dissolve urate, urate will crystallize and precipitate from the blood, and deposit in joints, soft tissues, cartilage, kidneys and other parts. The urate deposited in the joints causes an inflammatory reaction in the joints, resulting in gout-related symptoms such as severe pain, redness and swelling.

[0003] In vivo, xanthine oxidase is the key enzyme that decomposes purine into uric acid. Currently, drugs that reduce uric acid mainly include allopurinol and febuxostat that inhibit xanthine oxidase and benzbromarone that promotes diuresis and excretion. Studies have shown that the source of purine is self-metabolism (endogenous purine, 80%, uncontrollable factors) and food intake (exogenous, 20%, controllable factors), and the blood uric acid content increases with age. Endogenous purines are mostly adenine and guanine released after DNA damage, which are then converted into xanthine by xanthine oxidase and then converted into uric acid. The above three gout treatment drugs all have side effects to varying degrees, especially benzbromarone has been banned or withdrawn from the market in some European countries. Although controlling diet can reduce the generation of uric acid, it is easy to rebound and has limited effect. Therefore, the development of a composition that can effectively reduce uric acid has become a problem that urgently needs to be solved. This can not only ensure the quality of life of patients for a long time, but also reduce the risk of diseases related to hyperuricemia.

[0004] Celery seed extract is an extract of mature seeds of water celery and celery of the Umbelliferae family, containing volatile oil, apigenin, bergamot lactone, organic acid and other substances. Celery seed extract has a significant effect on reducing uric acid, and high doses are preferred (Effects of celery seed extract on blood uric acid and antioxidant capacity of hyperuricemia model rats, Medical Information, 2018, 31(13), 84-87). In addition to its strong antioxidant capacity, vitamin C also has the effect of reducing uric acid. Zeng Xianguo (Observation on the clinical effect of oral vitamin C in the treatment of hyperuricemia, Journal of Clinical Rational Drug Use. 2016, 9(27)) disclosed that VC treatment of hyperuricemia can effectively reduce the patient's blood uric acid level, and 500 mg is the best dosage. Vitamin B1, also known as thiamine, has the function of maintaining normal glucose metabolism. Jiang Shide (Study on the correlation between dietary vitamin B1 intake and patients with hyperuricemia, Chinese Medicine. 2020, 15(01)) disclosed that dietary vitamin B1 intake was negatively correlated with the prevalence of hyperuricemia in the general population and male population, but there was no correlation in the female population. Vitamin B2, also known as riboflavin, is a component of the body's flavonoids cofactor. If it is deficient, it will affect the body's biological oxidation and cause metabolic disorders. The lesions are mostly manifested as inflammation of the mouth and eyes, such as angular cheilitis, cheilitis, glossitis, conjunctivitis and orchitis. Ge Bing (Effects of vitamin B2 and vitamin B6 supplementation on hyperuricemia in rats, Chinese Food and Nutrition. 2018, 24(05)) disclosed that vitamins B2 and B6 can reduce the uric acid level of hyperuricemia rats to a certain extent. Summary of the invention

[0005] The object of the present invention is to provide a safe and effective composition for reducing uric acid. The composition acts on the pre-formation stage, the formation stage and promotes the degradation of uric acid based on various mechanisms of uric acid formation.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A safe and effective nutritional composition for reducing uric acid levels, comprising:

[0008] (1) an effective amount of celery seed extract;

[0009] (2) an effective amount of vitamin C;

[0010] (3) an effective amount of vitamin B;

[0011] Among them, the dosage ratio of celery seed extract, vitamin C and vitamin B is 200-1000:20-85:1-6.

[0012] In the present invention, the weight portion of the celery seed extract is 200 to 1000 parts, the weight portion of vitamin C is 20 to 85 parts, and the weight portion of vitamin B is 1 to 6 parts.

[0013] In the present invention, the vitamin C is composed of L-ascorbic acid and sodium L-ascorbate, wherein the usage ratio of L-ascorbic acid to sodium L-ascorbate is 0-5:5-0; the usage ratio of L-ascorbic acid to sodium L-ascorbate is preferably 5:2.

[0014] In the present invention, the vitamin B consists of vitamin B1, vitamin B2 and vitamin B9, wherein the usage ratio of vitamin B1, vitamin B2 and vitamin B9 is 800-3200:400-1600:40-208.

[0015] In the present invention, the vitamin B9 includes folic acid, 5-methyltetrahydrofolate, formyltetrahydrofolate, folinic acid, and calcium folinate. Among them, 5-methyltetrahydrofolate is preferably 6S-5-methyltetrahydrofolate calcium.

[0016] In a preferred embodiment of the present invention, the weight portion of the celery seed extract is 250 parts, the weight portion of L-ascorbic acid is 15 parts, the weight portion of L-sodium ascorbate is 6 parts, the weight portion of vitamin B1 is 0.8 parts, the weight portion of vitamin B2 is 0.4 parts, and the weight portion of folic acid is 0.04 parts.

[0017] In a preferred embodiment of the present invention, the weight portion of the celery seed extract is 250 parts, the weight portion of L-ascorbic acid is 15 parts, the weight portion of L-sodium ascorbate is 6 parts, the weight portion of vitamin B1 is 0.8 parts, the weight portion of vitamin B2 is 0.4 parts, and the weight portion of 6S-5-methyltetrahydrofolate calcium is 0.052 parts.

[0018] In a preferred embodiment of the present invention, the weight portion of the celery seed extract is 1000 parts, the weight portion of L-ascorbic acid is 15 parts, the weight portion of L-sodium ascorbate is 6 parts, the weight portion of vitamin B1 is 0.8 parts, the weight portion of vitamin B2 is 0.4 parts, and the weight portion of 6S-5-methyltetrahydrofolate calcium is 0.052 parts.

[0019] In a preferred embodiment of the present invention, the weight parts of celery seed extract are 500 parts, the weight parts of L-ascorbic acid are 30 parts, the weight parts of L-sodium ascorbate are 12 parts, the weight parts of vitamin B1 are 1.6 parts, the weight parts of vitamin B2 are 0.8 parts, and the weight parts of 6S-5-methyltetrahydrofolate calcium are 0.104 parts.

[0020] In a preferred embodiment of the present invention, the weight proportion of celery seed extract is 1000 parts, the weight proportion of L-ascorbic acid is 60 parts, the weight proportion of L-sodium ascorbate is 24 parts, the weight proportion of vitamin B1 is 3.2 parts, the weight proportion of vitamin B2 is 1.6 parts, and the weight proportion of folic acid is 0.08 parts.

[0021] In a preferred embodiment of the present invention, the weight parts of celery seed extract are 1000 parts, the weight parts of L-ascorbic acid are 60 parts, the weight parts of L-sodium ascorbate are 24 parts, the weight parts of vitamin B1 are 3.2 parts, the weight parts of vitamin B2 are 1.6 parts, and the weight parts of 6S-5-methyltetrahydrofolate calcium are 0.208 parts.

[0022] The nutritional composition of the present invention can be added with auxiliary materials to be prepared into oral dosage forms such as ordinary tablets, chewable tablets, soft capsules, hard capsules, powders, granules, solid beverages, etc.

[0023] In the present invention, the auxiliary materials are selected from one or a combination of fillers (dispersants), suspending agents, wetting agents, adhesives, disintegrants, lubricants, flavoring agents, stabilizers, embedding materials, coating premixes, and food colorings.

[0024] Among them, the filler (dispersant) described in the present invention includes one or more of starch, soluble starch, dextrin, maltodextrin, potato starch, corn starch, wheat starch, D-mannitol, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, maltose, xylitol, sorbitol, microcrystalline cellulose, isomaltulose, milk powder, low-substituted hydroxypropyl cellulose, sucrose, glucose, lactose, pregelatinized starch, edible vegetable oil, polyethylene glycol, etc.

[0025] The suspending agent of the present invention includes one or more of beeswax, insect wax, lecithin, glyceryl monostearate, ethyl cellulose, etc., the wetting agent includes purified water and ethanol, and the binder includes one or more of hydroxypropyl methylcellulose, povidone, hydroxypropyl cellulose, sodium carboxymethyl cellulose, starch, methyl cellulose, ethyl cellulose, gelatin, polyethylene glycol, pregelatinized starch, sucrose, glucose, etc.

[0026] The disintegrant of the present invention includes one or more of starch, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, sodium bicarbonate and citric acid, and the lubricant includes one or more of magnesium stearate, stearic acid, talc, silicon dioxide, hydrogenated vegetable oil, polyethylene glycol, sodium lauryl sulfate, glyceryl behenate, sodium stearyl fumarate, etc.

[0027] The flavor corrector of the present invention comprises one or more of fruit powder, edible flavor, high-intensity sweetener, acidulant and the like; the fruit powder comprises one or more of orange powder, lemon powder, cherry powder, apple powder, strawberry powder, strawberry powder, kiwi fruit powder, tangerine powder, sea buckthorn fruit powder, green plum fruit powder, mango fruit powder, mulberry fruit powder, hawthorn fruit powder, watermelon fruit powder, pineapple fruit powder, blueberry fruit powder, peach fruit powder, cantaloupe fruit powder, grape fruit powder, vanilla fruit powder, pomegranate fruit powder, rose fruit powder and the like.

[0028] The edible flavors described in the present invention include vanilla flavor, sweet orange flavor, milk flavor, apple flavor, grape flavor, strawberry flavor, pineapple flavor, peach flavor, cantaloupe flavor, lemon flavor, cherry flavor, sweet corn flavor, banana flavor, raisin flavor, grape flavor, rose flavor, blackcurrant flavor, green apple flavor, mango flavor, green mango flavor, orange flavor, orange flavor, snow pear flavor, strawberry flavor, green plum flavor, blueberry flavor, bayberry flavor, grapefruit flavor, pineapple flavor, guava flavor, passion fruit flavor, kiwi flavor, cherry flavor, kiwi flavor, watermelon flavor, papaya flavor, cantaloupe flavor, durian flavor, lychee flavor, hawthorn flavor, olive flavor, mulberry flavor, etc.

[0029] The high-intensity sweeteners described in the present invention include sucralose, aspartame, mogroside, neotame, and stevioside. The acidulants include citric acid, citric acid, malic acid, lactic acid, tartaric acid, and fumaric acid. The food pigments include one or more of caramel color, gardenia yellow, curcumin and chlorophyll, capsicum orange, capsicum red, grape skin red, carmine and its aluminum lake, sunset yellow and its aluminum lake, brilliant blue and its aluminum lake, indigo and its aluminum lake, beetroot red, natural amaranth, gardenia blue, plant carbon black, black iron oxide, red iron oxide, black bean red, quinoline yellow, lycopene, red monascus, yellow iron oxide, cocoa shell color, safflower yellow, and monascus yellow pigment.

[0030] The stabilizer described in the present invention includes vitamin E, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and vitamin C. The embedding material includes one or more of β-cyclodextrin, α-cyclodextrin, γ-cyclodextrin, dextrin, starch, edible modified starch, sucrose, maltodextrin, gum arabic, and the like.

[0031] The present invention also provides the use of the above nutritional composition in preparing a product capable of reducing uric acid. The above product is not limited to food, health care products, health food, functional food, medicine, etc.

[0032] The present invention also provides a method for preparing the above nutritional composition, the steps comprising:

[0033] 1. Mix celery seed extract, L-ascorbic acid, sodium L-ascorbate, vitamin B1, vitamin B2 and 6S-5-methyltetrahydrofolate calcium for 5 minutes, and pass the mixture through a 50-mesh sieve to obtain mixture I.

[0034] 2. Mix mixture I and other auxiliary materials for 15 minutes to obtain a total mixed powder.

[0035] The present invention screens celery seed extract, vitamin C, and vitamin B with synergistic functions for scientific formulation. By selecting the optimal dosage of the composition components, not only can the uric acid level be significantly and synergistically reduced, but also uric acid excretion can be promoted, so that the uric acid level of patients with hyperuricemia can be quickly controlled, thereby preventing gout attacks, relieving pain, and treating gout. Compared with existing products, the present invention is a safer and more effective composition product, and its effect is also significantly stronger than the single application effect of the components, and it has an unexpected synergistic effect in reducing uric acid. It can be used for daily health care of patients with hyperuricemia, is safe and has no side effects, and also has the function of assisting in preventing cardiovascular diseases.

[0036] The embodiments of the present invention are further described below in conjunction with examples. DETAILED DESCRIPTION

[0037] Example 1: Preparation of the nutritional composition granules of the present invention

[0038] 1. Raw material composition: 250 g of celery seed extract, 15 g of L-ascorbic acid, 6 g of sodium L-ascorbate, 0.8 g of vitamin B1, 0.4 g of vitamin B2, and 40 mg of folic acid;

[0039] 2. Auxiliary ingredients: xylitol 278g

[0040] 3. Preparation method: (1) Determine the moisture content of each raw material and auxiliary material and control the moisture content to ≤5.0%; weigh each raw material and auxiliary material according to the formula; (2) Mix L-ascorbic acid and sodium L-ascorbate, vitamin B1 and vitamin B2 for 5 minutes, pass through a 50-mesh sieve, add other auxiliary materials and mix for 15 minutes; (3) Use aluminum-plastic composite film to pack the material obtained in step (2) into 1000 bags, each bag weighing 3 grams.

[0041] Example 2: Preparation of the nutritional composition granules of the present invention

[0042] 1. Raw material composition: 1000 g of celery seed extract, 60 g of L-ascorbic acid, 24 g of sodium L-ascorbate, 3.2 g of vitamin B1, 1.6 g of vitamin B2, and 208 mg of 6S-5-methyltetrahydrofolate calcium;

[0043] 2. Auxiliary ingredients: xylitol 411g

[0044] 3. Preparation method: (1) Determine the moisture content of each raw material and auxiliary material and control the moisture content to ≤5.0%; weigh each raw material and auxiliary material according to the formula; (2) Mix L-ascorbic acid and sodium L-ascorbate, vitamin B1 and vitamin B2 for 5 minutes, pass through a 50-mesh sieve, add other auxiliary materials and mix for 15 minutes; (3) Use aluminum-plastic composite film to pack the material obtained in step (2) into 1000 bags, each bag weighing 1.5 grams.

[0045] Example 3: Effect of the nutritional composition of the present invention on uric acid levels in experimental animals

[0046] SPF grade Kunming mice, male, 20-22g. After 5 days of animal adaptation, 10 mice were selected as the blank control group, and the rest of the animals were gavaged with hypoxanthine (250 mg / kg) and potassium oxonate (300 mg / kg) suspension every day for 7 consecutive days. The drugs given by gavage after successful modeling are shown in Table 1. The blank control group and the model group were given the same amount of normal saline every day. The dosage of celery seed extract + folic acid in celery seed folic acid group 1 was (35.7+0.006) mg / kg [the corresponding human dosage is (250+0.04) mg]; the other groups are shown in Table 1. For 20 consecutive days. After the last administration, fasting but not water restriction was performed for 24 hours. The mouse urine was collected for 24 hours using a mouse metabolic cage, and the UA in the collected urine was determined. The serum uric acid (UA) content was detected using a uric acid test kit (Nanjing Jiancheng Bioengineering Institute). The mouse eyeballs were removed for blood collection. After blood was drawn from the mice, they were killed, the abdominal cavity of the mice was opened, the liver was quickly taken out, part of the liver was weighed and mixed with physiological saline, homogenized and centrifuged, and the xanthine oxidase test kit (Nanjing Jiancheng Bioengineering Institute) and adenosine deaminase enzyme-linked immunosorbent assay (ELISA) kit (Suzhou Colvin Biotechnology Co., Ltd.) of mouse liver tissue homogenate in the supernatant were used to detect the activities of xanthine oxidase (XOD) and adenosine deaminase (ADA).

[0047] The Jin Zhengjun Q value method was used to analyze the effect of the two components.

[0048] [Jin Zhengjun, Zhang Xiaowen, Equiprobability and curve and Q5e - a new method for estimating the effect of combined medication, Journal of Shanghai Second Medical College, 1981] Also known as the probability addition method, according to the pharmacological effects of the combination of two drugs and the pharmacological effects of the two drugs alone in the dose-effect curve area, Q = E is calculated using the following formula A+B / (E A TenE B -E A *E B), where the numerator represents the "measured combined effect" and the denominator represents the "expected combined effect". (To satisfy the analysis of the pharmacological action relationship of the components and the composition, their pharmacological actions are converted into effects that can intuitively reflect the strength of the pharmacological action. The calculation formula: E i = 1 - P i / P 模型组 , P i is the pharmacological index of each component, and P 模型组 is the pharmacological index of the model group), and Q is the ratio of the two. When Q < 0.85, the combination of the two drugs is considered an antagonistic effect; when 0.85 < Q < 1.15, it is considered an additive effect; when Q > 1.15, it is considered a synergistic effect.

[0049] SPSS 20.0 was used to analyze the data. Measurement data were expressed as mean ± standard deviation, and the t-test was used.

[0050] Table 1. Grouping and Dosage

[0051]

[0052] Table 2. Effects of the Composition of the Present Invention on the Activities of Uric Acid, Xanthine Oxidase and Adenosine Deaminase in Mice (n = 9 - 10, )

[0053]

[0054] Compared with the model group, *P < 0.05, **P < 0.01

[0055] The above experimental results show that after modeling with hypoxanthine and potassium oxonate, compared with the blank control group, the uric acid level, XOD and ADA activities of the model group mice were significantly increased, indicating that the modeling of hyperuricemic mice was successful.

[0056] Compared with the model group, UA, XOD and ADA in Celery Seed Folic Acid Group 1 and Celery Seed Folic Acid Group 2 were significantly decreased, showing statistical differences, which was consistent with the results of our previous studies.

[0057] Compared with the model group, there were no significant differences in the uric acid level, XOD and ADA activities of the mice in Vitamin Group 1, Vitamin Group 2 and Vitamin Group 3. Although there are existing reports that the levels of vitamin B1, vitamin B2 and vitamin C in the body are related to the uric acid level, the supplementation dosages disclosed in the existing reports are very high. For example, Zeng Xianguo (Observation on the Clinical Effect of Oral Vitamin C in the Treatment of Hyperuricemia, Chinese Journal of Clinical Rational Drug Use. 2016, 9(27)) disclosed that 500 mg VC was the optimal dosage for the treatment of hyperuricemia; while in this application, the dosage of vitamin C converted to adults is only 21 - 84 mg, which is much lower than the dosage disclosed in the prior art.

[0058] Compared with the model group, UA, XOD and ADA in composition group 1, composition group 2, composition group 3 and composition group 4 were significantly decreased, showing significant or extremely significant statistical differences, indicating that celery seed extract combined with folic acid (or 6S-5-methyltetrahydrofolate calcium), vitamin C, vitamin B1 and vitamin B2 can significantly improve hyperuricemia. The Q values ​​of composition group 1, composition group 3 and their corresponding components on UA, XOD and ADA were all greater than 1.15, while the Q values ​​of composition group 2 and composition group 4 were less than 1.15; the dosage of celery seed extract + folic acid in composition group 1 and composition group 2 was (35.7 + 0.006) mg / kg, the dosage of vitamin C + vitamin B1 + vitamin B2 in composition group 1 was (3 + 0.1 + 0.06) mg / kg, and the dosage of vitamin C + vitamin B1 + vitamin B2 in composition group 2 was (48 + 1.6 + 0.96) mg / kg; the dosage of celery seed extract + 6S-5-methylpyrrolidone in composition group 3 and composition group 4 was (48 + 1.6 + 0.96) mg / kg. The dosage of calcium tetrahydrofolate was (142.8+0.028) mg / kg, the dosage of vitamin C+vitamin B1+vitamin B2 in composition group 3 was (12+0.4+0.24) mg / kg, and the dosage of vitamin C+vitamin B1+vitamin B2 in composition group 4 was (48+1.6+0.96) mg / kg; this indicates that the composition of vitamin C+vitamin B1+vitamin B2 with a dosage of (48+1.6+0.96) mg / kg begins to show a preliminary uric acid-lowering effect due to its relatively high dosage, and its effect on lowering uric acid by celery seed extract combined with folic acid (or 6S-5-methyltetrahydrofolate calcium) is no longer a synergistic effect. That is, as the dosage of vitamin C, vitamin B1 and vitamin B2 increases, the synergistic effect of vitamin C, vitamin B1 and vitamin B2 on celery seed extract combined with folic acid (or 6S-5-methyltetrahydrofolate calcium) in reducing uric acid is weakened, which also shows that the dosage range of the synergistic composition provided by the present invention is carefully selected.

Claims

1. A nutritional composition for lowering uric acid, comprising: (1) an effective amount of celery seed extract; (2) an effective amount of vitamin C; (3) an effective amount of vitamin B; in, The dosage ratio of celery seed extract, vitamin C and vitamin B is 200-1000:20-85:1-6.

2. The nutritional composition according to claim 1, characterized in that: The weight proportion of the celery seed extract is 200 to 1000 parts, the weight proportion of vitamin C is 20 to 85 parts, and the weight proportion of vitamin B is 1 to 6 parts.

3. The nutritional composition according to claim 2, characterized in that: The vitamin C is composed of L-ascorbic acid and sodium L-ascorbate, wherein the usage ratio of L-ascorbic acid to sodium L-ascorbate is 0-5:5-0; the usage ratio of L-ascorbic acid to sodium L-ascorbate is preferably 5:

2.

4. The nutritional composition according to claim 2, characterized in that: The vitamin B consists of vitamin B1, vitamin B2 and vitamin B9, wherein the usage ratio of vitamin B1, vitamin B2 and vitamin B9 is 800-3200:400-1600:40-208.

5. The nutritional composition according to claim 4, characterized in that: The vitamin B9 includes folic acid, 5-methyltetrahydrofolate, folinic acid, folinic acid and calcium folinate.

6. The nutritional composition according to claim 5, characterized in that: The 5-methyltetrahydrofolate is 6S-5-methyltetrahydrofolate calcium.

7. The nutritional composition according to claim 5 or 6, characterized in that: The weight portion of the celery seed extract is 250 parts, the weight portion of L-ascorbic acid is 15 parts, the weight portion of L-ascorbic acid sodium is 6 parts, the weight portion of vitamin B1 is 0.8 parts, the weight portion of vitamin B2 is 0.4 parts, and the weight portion of folic acid is 0.04 parts; Or the weight portion of the celery seed extract is 250 parts, the weight portion of L-ascorbic acid is 15 parts, the weight portion of L-ascorbic acid sodium is 6 parts, the weight portion of vitamin B1 is 0.8 parts, the weight portion of vitamin B2 is 0.4 parts, and the weight portion of 6S-5-methyltetrahydrofolate calcium is 0.052 parts; Or the weight portion of the celery seed extract is 1000 parts, the weight portion of L-ascorbic acid is 15 parts, the weight portion of L-ascorbic acid sodium is 6 parts, the weight portion of vitamin B1 is 0.8 parts, the weight portion of vitamin B2 is 0.4 parts, and the weight portion of 6S-5-methyltetrahydrofolate calcium is 0.052 parts; Or the weight portion of the celery seed extract is 1000 parts, the weight portion of L-ascorbic acid is 60 parts, the weight portion of L-ascorbic acid sodium is 24 parts, the weight portion of vitamin B1 is 3.2 parts, the weight portion of vitamin B2 is 1.6 parts, and the weight portion of folic acid is 0.08 parts Or the weight portion of celery seed extract is 1000 parts, the weight portion of L-ascorbic acid is 60 parts, the weight portion of L-sodium ascorbate is 24 parts, the weight portion of vitamin B1 is 3.2 parts, the weight portion of vitamin B2 is 1.6 parts, and the weight portion of 6S-5-methyltetrahydrofolate calcium is 0.208 parts.

8. The nutritional composition according to any one of claims 1 to 7, characterized in that: The composition can be added with auxiliary materials to prepare oral dosage forms such as common tablets, chewable tablets, soft capsules, hard capsules, powders and granules.

9. Use of the nutritional composition according to any one of claims 1 to 7 in the preparation of a product capable of reducing uric acid.